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Abstract Diphtheria toxin (DT) has attracted considerable effect. Thirdly, because of its immunogenicity, the administra- 
attention for anti-cancer therapy. However, its extensive use is tion of DT will result in a drastic increase in the serum levels 
prohibited by (i) its non-specific action which can result in of AT antibodies within 2 weeks after administration, thereby 
substantial toxicity, (ii) most patients have low serum levels of further compromising the antitumor activity. Intravenous ad- 
anti-DT antibodies (AT antibodies) which can inactivate DT and ministration of DT on 3 consecutive days to 50 patients with 
(iii) its immunogenicity will boost the circulating AT antibody advanced solid tumors resulted in an overall response rate of 
level, thereby further compromising the antitumor activity. To 48% [5]. However, when the responders were treated again 
overcome these limitations, we have developed a new approach with DT after regrowth of tumor lesions, no additional re- 
for targeted delivery of DT utilizing immunoliposomes. In this sponses were observed, probably because of the presence of 
approach, protection against the non-specific action of DT is neutralizing AT antibodies. 
combined with efficient antitumor activity even in the presence of To enhance its target cell specificity (e.g. towards tumor 
inactivating AT antibodies, cells), complete DT or the enzymatic active part of DT (frag- 
Key words." Diphtheria toxin; Immunoliposome; Targeted ment A: DTA) has been coupled to monoclonal antibodies 
drug delivery; Monoclonal antibody; Ovarian cancer (immunotoxins; reviewed in e.g. [6]). For the same purpose, 
DTA has been encapsulated in pH-sensitive antibody-directed 
liposomes (immunoliposomes [7,8]). Knowledge of the struc- 
tural and functional properties of several toxins, as well as the 
1. Introduction development of recombinant techniques have made it further- 
more possible to construct fusion proteins in which the native 
During the past two decades, diphtheria toxin (DT) has receptor binding domain of DT is replaced by, e.g. growth 
attracted considerable attention for its potential use in cancer factors [3,6,9]. 
therapy [1-3]. DT produced by Corynebacterium diphtheriae is It has been reported that circulating neutralizing AT anti- 
toxic to most eukaryotic ells. It inhibits protein synthesis via bodies strongly limit the therapeutic use of DT immunotoxins 
ribosylation of elongation factor 2. An attractive feature of by early inactivation of the toxin and will particularly inter- 
toxins like DT is that they are also able to kill non-dividing fete in multiple injection schemes [10,11]. As an alternative to 
cells, which many conventional chemotherapeutic drugs do this approach, we have developed an entirely new concept for 
not [4]. Three major factors prohibit the extensive use of the targeted elivery of DT. Immunoliposomes are able to 
DT in cancer therapy. Firstly, its non-specific action can bind to tumor cells in vitro and in vivo if located at a body 
lead to severe side effects. Secondly, as in the industrialized site that can be reached by the immunoliposomes [12-16]. 
countries most people are vaccinated against diphtheria, over Because it is difficult for immunoliposomes to pass from one 
80% of the population have low serum levels of anti-diphthe- body compartment (e.g. blood) to another, potential target 
ria toxin antibodies (AT antibodies). These circulating AT sites must be selected carefully. Target cells in the blood- 
antibodies can inactivate DT, thereby inhibiting the antitumor stream, lymph nodes, and body cavities uch as the peritoneal 
cavity, pleural cavity, uterus, and bladder can be reached by 
immunoliposomes after intravenous or local administration. 
*Corresponding author. Fax (31) (30) 51 7839. That immunoliposomes can be targeted efficiently to tumor 
Abbreviations. AT antibodies, anti-diphtheria toxin antibodies; AU, cells was shown by, e.g. Nfissander et al [13] and Ahmad et 
antibody unit; CHOL, cholesterol; DMEM, Dulbecco's modified al. [14]. Immunoliposomes were able to bind rapidly and effi- 
Eagle's medium; DT, diphtheria toxin; DTA, diphtheria toxin ciently (i.e. more than 80% of the administered i.p. dose) to 
fragment A; DTT, dithiothreitol; EPC, egg phosphatidylcholine; human ovarian carcinoma cells located in the peritoneal cav- 
EPG, egg phosphatidylglycerol; FCS, fetal calf serum; Lf, limit of 
flocculation (quantity of DT that flocculates most rapidly when mixed ity of nude mice [13]. In lung carcinoma-bearing animals in- 
with 1 unit of antitoxin); MPB-PE, N-[4-(p-maleimidophenyl)butyr- creased lung uptake of i.v. administered long-circulating im- 
yl]phosphatidylethanolamine; PE, phosphatidylethanolamine; SMPB, munoliposomes was observed compared to that in non-tumor- 
succinimidyl 4-(p-maleimidophenyl)butyrate; SRB, sulforhodamine-B; bearing animals [14]. 
TL, total ipid (phospholipid+cholesterol) We hypothesized that encapsulation i to immunoliposomes 
(i) UIPS is participant in the Groningen Utrecht Institute for Drug may protect DT against inactivation by circulating neutraliz- 
Exploration (GUIDE). ing AT antibodies. After binding to the tumor cells, DT may 
0014-5793/96/$12.00 © 1996 Federation of European Biochemical Societies. All rights reserved. 
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free DT DT-immunoliposomes 
Fig. 1. Schematic representation f the proposed approach: protection against inactivating AT antibodies by incorporation of DT in tumor-spe- 
cific immunoliposomes. DT (0 )  administered as free drug and premature released DT from DT immunoliposomes is inactivated by circulating 
AT antibodies (-<). By encapsulating DT in tumor-specific mmunoliposomes, it is protected against he circulating AT antibodies and deliv- 
ered in close proximity to the target cell, where it can exert its action upon leakage from cell-bound immunoliposomes. 
leak out of the target cell-bound immunol iposomes in close ness in a rotary evaporator under educed pressure. After flushing the 
proximity to the tumor cell (nanometer range), subsequently lipid film with nitrogen (->20 min), the lipid film was hydrated with a 
DT solution (RIVM DT79-I; 55 ~tmol total lipid (TL)/ml; 500 Lf/ml 
bind to its receptor, translocate into the cytoplasm and induce in 10 mM HEPES, 75 mM NaCI, 0.5 mM EDTA, pH 7.4; Lf denotes 
an ant i tumor effect. In addit ion to the protective effect of the limit of flocculation, i.e. the quantity of DT that flocculates most 
immunol iposome encapsulation, a second advantage of this rapidly when mixed with 1 unit of antitoxin; 1 Lf roughly corresponds 
system is that prematurely released DT, i.e. DT  released prior with about 2 I.tg pure DT and about 1/35 MLD (minimal ethal dose 
in guinea pigs)). The resulting liposome dispersion was sequentially 
to the actual binding of the immunol iposomes to the target extruded through polycarbonate membrane filters of 0.6 and 0.2 ~tm 
cell and therefore potentially toxic, will be inactivated by the pore size which resulted in a mean particle size of approx. 0.25 Ixm. 
circulating AT antibodies. A schematic representation of the After extrusion the liposomes were centrifuged (100000xg; 30 min) 
proposed therapeutical approach of DT  exploiting the pres- and the pellet was redispersed in 100 mM acetate buffer pH 6.5 (with 
ence of AT  antibodies is given in Fig. 1. 40 mM NaC1 and 1 mM EDTA). The freshly prepared liposomes were 
mixed with freshly prepared Fab' fragments (concentrations during 
Here we provide evidence that the proposed hypothesis is incubation ranged from 6 to 12 ~mol TL/ml and from 0.25 to 0.30 mg 
realistic. DT  encapsulated in tumor-specific immunol iposomes Fab'/ml, respectively). The coupling reaction was carried out over- 
is highly active against in vitro cultured tumor cells when AT night at 4°C with constant rotation under a nitrogen atmosphere. 
antibodies are present in the incubation medium. Under  the Finally, the immunoliposomes were separated from unconjugated 
Fab' fragments by ultracentrifugal sedimentation at 100000xg for same conditions, free DT and DT encapsulated in non-tar-  30 min. The pellet was resuspended and washed twice with HEPES 
geted liposomes do not display toxicity towards the tumor buffer (20 mM HEPES, 149 mM NaCI, 1 mM EDTA, pH 7.4). MPB- 
cells. PE-containing liposomes not incubated with Fab' fragments are re- 
ferred to as 'unconjugated liposomes' throughout this paper. Lipo- 
2. Materials and methods some dispersions were stored at 4°C and used within 3 weeks. 
2.1. Monoclonal antibody 2.3. Liposome characterization 
All antibodies used in this study are mouse monoclonal antibodies Lipid phosphate was determined by the colorimetric method of 
Fiske and Subbarow [25]. The amount of antibody coupled to the of the IgG1 type. The monoclonal antibody OV-TL3 is directed 
against he OA3 antigen, present on over 90% of human ovarian liposomes was determined according to the method of Wessel and 
carcinomas [17,18]. The antibody 323/A3 recognizes a 43 kDa mem- FKigge [26], with bovine serum albumin as standard and was ex- 
brane glycoprotein which is highly expressed on a variety of carcino- pressed as ~tg of Fab' per Ixmol of TL. DT was determined fluorime- 
mas [19,20]. The monoclonal antibody RIV1000, in the present study trically, after solubilization of the liposomes in Tween 80, using fluor- 
escamine (Pierce, Rockford, USA; excitation wavelength, 390 nm; used as an irrelevant antibody, is directed against human lymphocytes 
[21,22]. emission wavelength, 476 nm [27]). Mean particle size was determined 
F(ab')2 fragments of the monoclonal antibodies (Centocor Europe by dynamic light scattering with a Malvern 4700 system (Malvern 
BV, Leiden and RIVM, National Institute of Public Health and En- Ltd., Malvern, UK). 
vironmental Protection, Bilthoven, The Netherlands) were digested 
with 20 mM dithiothreitol as described earlier [12,23] and used im- 2.4. Antitumor activity in vitro 
mediately for covalent attachment to freshly prepared liposomes (see The human ovarian cancer cell line OVCAR-4 [28] was maintained 
below), in Dulbecco's modified Eagle's medium (Flow Laboratories, Irving, 
UK) supplemented with 10% fetal calf serum (Gibco Ltd., Paisley, 
2.2. Preparation of immunoliposomes UK), glutamine (2 mM), penicillin (100 units/ml), streptomycin (100 
Egg phosphatidylcholine (EPC) and egg phosphatidylglycerol lag/ml), and amphotericin B (0.26 btg/ml). 
(EPG) were donated by Lipoid GmbH (Ludwigshafen, Germany). In vitro cell growth inhibition induced by DT and DT-(immuno)- 
Cholesterol (CHOL) was obtained from Sigma Chemical Co. (St. liposomes was determined by the SRB assay based on the use of the 
Louis, USA). N-[4-(p-Maleimidophenyl)butyryl]phosphatidylethano- dyesulforhodamine-B (SRB [29,30]). Briefly, monolayers of OVCAR- 
lamine (MPB-PE) was synthesized, purified and analyzed as described 4 were treated with trypsin/EDTA (0.25%10.02%) and washed with 
before [12,24]. MPB-PE was incorporated into the liposomal bilayers medium. To mimic a therapeutically relevant situation, incubations 
to allow covalent coupling of Fab' fragments to the liposomal surface, were performed with cells in suspension. Cells (1 × l0 s cells/ml) were 
The bilayer composition of the liposomes used was EPC:EPG: incubated (90 min, 37°C) with DT in free form or DT encapsulated in 
CHOL:MPB-PE at a molar ratio 38.1:4:16:1.5. A mixture of the (immuno-)liposomes in the presence or absence of anti-diphtheria 
appropriate amounts of lipids in chloroform was evaporated to dry- toxin antibodies (AT antibodies; Institute Pasteur Production, Paris, 
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France). After incubation, unbound liposomes, DT and AT anti- 120 
bodies were removed by centrifugation (500 x g; 5 min). The cell pellet relative cell growth 
was washed twice and resuspended in culture medium with or without (%) 100 
AT antibodies. Then, 5 X 104 cells per well were seeded in a flat-bot- 
tom 96-well plate and cultured for 72 h at 37°C and 5% CO2. The 8O cultures were fixed, stained and measured as described earlier [29,30]. 
The cytotoxic activity of DT was measured as the degree of cell pro- 
liferation relative to that of untreated cells (=100%). ICs0 values in- 60 
dicate the DT concentration which results in 50% cell growth com- 
pared to untreated cells. 40 
2.5. Statistics 20- 
The effect of different reatments was compared by a two-tailed 
Student's t-test assuming equal variances with 95% confidence inter- 0 -~ 
val. Differences were considered significant when the p value of com- 0 0.2 0.4 0.6 0.8 1 1.2 
parison was less than 0.05. 
AT-antibody concentration (AU/ml) 
3. Results Fig. 3. Effect of the presence of AT antibodies on the in vitro anti- 
tumor activity of free DT and DT encapsulated in two types of spe- 
3.1. Antitumor activity of DT cific immunoliposomes. A suspension of OVCAR-4 cells was incu- 
bated with 0.3 Lf/ml free DT (O) or DT encapsulated in 323/A3- 
DT was encapsulated in liposomes using the classical film (D) or OV-TL3 immunoliposomes (I) for 90 min at 37°C in the 
method followed by extrusion (so-called extrusion MLV). The presence of AT antibodies (0, 0.3 or 1.0 AU/ml). After removal of 
encapsulation efficiency was about 5% (on average about 0.44 AT antibodies, free DT and unbound immunoliposomes, cells were 
Lf/pmol TL), suggesting that DT is located in the internal cultured for 72 h in AT antibody free medium and relative cell 
growth was measured using the SRB assay. Results are given as 
aqueous phase of the liposomes. We first evaluated the effect mean _+ S.D. of 3-9 separate xperiments. The Fab' densities of the 
of immunoliposome encapsulation on the cytotoxic capacity 323/A3 and OV-TL3 immunoliposomes were 22 _+ 12 and 21 + 7 I.tg 
of DT in the absence of AT antibodies. In line with expecta- Fab'/~tmol TL, respectively. 
tigris, DT encapsulated in tumor-specific OV-TL3 immunoli- 
posomes was less active than free DT (Fig. 2). The ICs0 values 3.2. Effect of A T antibodies on the antitumor activity of DT 
were about 0.002 and 0.02 Lf/ml for DT in free form and DT Fig. 3 shows that free DT can be completely inactivated by 
immunoliposomes, respectively. Immunoliposomes devoid of AT  antibodies. A 3-fold excess of AT antibodies (1 antibody 
DT did not influence the cell growth at the lipid concentra- unit (AU)/ml) was sufficient o neutralize completely the anti- 
tions used (not shown). The antitumor activities of both free tumor effect of free DT at 0.3 Lf/ml (relative cell growth 
DT and DT immunoliposomes did not increase for DT con- 97 + 10%o). In line with the proposed concept, at the AT anti- 
centrations ->0.3 Lf/ml. At DT concentration of 0.3 Lf/ml, body concentration of 1 AU/ml, 323/A3 and OV-TL3 DT 
there was no difference in antitumor activity between free immunoliposomes were still cytotoxic (relative cell growth 
DT and DT encapsulated in targeted liposomes (i.e. 323/A3 19 + 21 and 15 + 10%o, respectively). In contrast, as shown in 
and OV-TL3 immunoliposomes). Therefore, this DT concen- Fig. 4A, DT encapsulated in non-targeted liposomes (uncon- 
tration was used in the experiments designed to evaluate the jugated liposomes, bar D; RIV1000 immunoliposomes, bar E) 
effect of the presence of AT antibodies on the antitumor ac- were by far much less effective in the presence of AT antibod- 
tivity of DT immunoliposomes, ies (1 AU/ml) as compared to DT in targeted liposomes (bars 
B,C, relative cell growth unconjugated liposomes and 
RIV1000 immunoliposomes was 85 + 12 and 84 + 15%, respec- 
100 a_  tively). The AT antibodies themselves did not affect cell 
relative cell growth ~ growth at the concentrations used (Fig. 4A, bar F). 
(%) i In the experiments shown in Figs. 3 and 4A, AT antibodies 80 
were present during the 1.5 h incubation period of DT (lipo- 
somes) with the tumor cells. In the experimental set-up used, 
60 DT, AT antibodies and unbound liposomes were removed 
after the 1.5 h incubation period, and the cells were cultured 
40 for 72 h in AT antibody free medium, before the actual cell 
growth determination. To mimic a more therapeutically rele- 
20 ~ vent situation, we also studied the cytotoxic effects when the 
AT antibodies were not removed uring the 72 h culture per- 
0 ........ r ........ ~ ........ ~ ........ i ........ ~ iod (Fig. 4B). Despite the resulting 3-fold decrease in cyto- 
0.0001 0.001 0.01 0.1 1 10 toxicity, tumor-specific DT immunoliposomes were still sub- 
DTconcentration(kf/ml) stantially more active than unconjugated DT-liposomes 
Fig. 2. In vitro antitumor activity of free DT and DT encapsulated (P < 0.003) and free DT (p < 0.002). 
in tumor-specific immunoliposomes. A suspension of OVCAR-4 In order to demonstrate that cell binding is a crucial re- 
cells was incubated with free DT (O) or DT encapsulated in OV- quirement for achieving cytotoxic effects of DT immunolipo- 
TL3 immunoliposomes (O) for 90 min at 37°C. After removal of somes, we studied whether prolonged exposure of tumor cells 
unbound DT or DT immunoliposomes, cells were cultured for 72 h to unconjugated DT-liposomes can confer some degree of 
and relative cell growth was measured using the SRB assay. The re- cytotoxicity. Tumor cells were incubated for 1.5 h with un- 
suits shown are derived from 2-4 separate xperiments. The Feb' 
density on OV-TL3 immunoliposomes was about 10 I-tg Fab'/~nol conjugated DT-liposomes (0.3 Lf/ml). After the removal of 
TL. unbound liposomes and AT antibodies, the cells were seeded 
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12o 1 A the lack of tumor cell specificity. An additional l imiting factor 
relative eeu growth t . . . . . .  is that, because of vaccination programs, most people have 
(%) loo ... .. -~::~.-_- low levels of circulating AT antibodies. Furthermore,  an in- 
T ~ crease in circulating AT ant ibody levels occurs within 2 weeks 
.. . .  (~::1::~,::~,~ .... after DT  administrat ion [11]. These AT antibodies can inacti- 
~i~:~' D~::::~ ::-:~:-::-::: vate DT prior to reaching the tumor cells. To overcome these 60 ~ ~:~"~~ ;~ I  
N problems, we a new concept utilizing a have evaluated in vitro 
~. '~ ~i::i::~'..'.:~iiN -,~.,.~ . . . . .  tumor-specific l iposomal delivery system for DT (Fig. 1). Li- 
40 i:~ii~%~ - - :  ~ '~ posomes can be targeted to tumor cells by coupling tumor- 
20 ~ ~ i:i~g~i:.i::~ii:~ iiii!;i:ii specific monoclonal  antibodies to the surface (immunolipo- 
~:~:~:~:~:,.::~ Niiii!~iii:~iiii somes), thereby increasing the specificity of the treatment 
0 ~ , ~ ~ ~ and reducing the non-specific action of DT [16]. We demon- 
A B C D E F strate here that, simultaneously, the encapsulation of DT in 
immunol iposomes offers an escape from early inactivation by 
circulating AT antibodies. In addit ion to this protective ffect 
120- B provided by immunoliposomes, prematurely released DT, i.e. 
relative coil growth , ,  , .  
(%) ~00 - DT  released from immunol iposomes which did not yet bind to 
~ ..:~.i" the target cells and therefore potentially toxic, will be inacti- 
N a0 - ~ vated by the circulating AT  antibodies. 
°~ i'i:i ~ As shown in Figs. 3 and 4A, DT encapsulated in tumor- 
60-  ~ ~  ........ specific immunol iposomes is highly active against in vitro tu- 
40 - mor growth in the presence of AT antibodies. Free DT and 
20-  
~oo- A 
0 : '":< : : :"  r ~ relative cell growth o gg/tamol TL 
A B C D E F (%l 80- 
Fig. 4. Effect of the presence of AT antibodies on the in vitro anti- 
tumor activity of DT encapsulated in targeted and non-targeted li- 60- ~o ~/w,o~ TL
posomes. OVCAR-4 cells in suspension were incubated with 0.3 Lf/ 
ml DT for 90 min at 37°C in the presence of AT antibodies (1.0 40- 
AU/ml). After removal of AT antibodies, free DT and unbound li- 
posomes, cells were cultured for 72 h in AT antibody free (A) or 
AT antibody containing (B) medium and relative cell growth was 20- 13p.g/pmolrL 
measured using the SRB assay. Results are given as mean + S.D. of " 23 lag/grnol TL
3-9 separate xperiments. *p<0.05, **p<0.01, ***p<0.001 (A, C-F oJ - I I l I a ~l~a~l/lamolrL 
VS B). Bars: A, free DT; B, DT in 323/A3 immunoliposomes (Fab' 0 0.2 0.4 0.6 0.a ~ ~.2 
density 22+ 12 gg/gmol TL); C, DT in OV-TL3 immunoliposomes 
(Fab' density 21 +7 gg/gmol TL); D, DT in unconjugated lips- AT-antibody concentration (AU/ml) 
somes; E, DT in non-specific immunoliposomes (Fab' density 
(RIV1000) 22+ 9 gg/gmol TL); F, control (AT antibodies alone). 
and cultured for 72 h in the presence of AT antibodies to- 
gether with 0.03 Lf/ml unconjugated DT-l iposomes (which 100- o 0,~,~TL 
relative ce l l  g rowth  . 
roughly corresponds with the fraction of cell=bound immune= (%) 10 la~w'nol TL 
liposomes). No cytotoxicity was observed (results not shown), s0- 13 g0 / l tmo l  TL 
which indicates that cell binding of DT immunol iposomes is 
mandatory  for ant i tumor action. 60- 
23 p.g/larnol TL It was shown earlier by N/issander et al. [12,13] that the 40- 
degree of cell binding of immunol iposomes depends on the 
Fab'  density on the liposomes (i.e. the amount  of Fab '  20- ~,~arL  
coupled to the liposomes expressed as gg Fab ' /gmol  TL): 
the higher the Fab '  density, the greater the degree of cell o I , , , ~ 
binding. Fig. 5 shows that a higher Fab '  density of 323/A3 o 0.2 0.4 0.6 0.8 1 1.2 
DT immunol iposomes is paralleled by an increase in the anti- AT-antibody concentration (AU/ml) 
tumor effect of these immunol iposomes in the presence of AT 
antibodies. These results again indicate that the irnmunolipo- Fig. 5. Effect of the Fab' density of 323/A3 DT immunoliposomes 
on the vitro antitumor activity in the presence of AT antibodies. A
somes need to bind to the target cell in order to be able to suspension of OVCAR-4 cells was incubated with 0.3 Lf/ml DT en- 
exert ant i tumor activity in the presence of AT antibodies, capsulated in 323/A3 immunoliposomes with different Fab' densities 
for 90 min at 37°C in the presence of AT (0, 0.3 or 1.0 AU/ml). 
4. Discussion After removal of AT, and unbound DT immunoliposomes, cells 
were cultured for 72 h in AT-free (A) or AT-containing (B) medium 
and relative cell growth was measured using the SRB assay. The 
DT is a potent inhibitor of protein synthesis in human cells. Fab' density of 323/A3 immunoliposomes was 0 (O), 10 (O), 13 
Its use for cancer treatment, however, is strongly limited by ([]), 23 (11), and 34 (zx) l.tg Fab'/gmol TL. 
M.H. Vingerhoeds et al./FEBS Letters 395 (1996) 245-250 249 
DT encapsulated in non-targeted liposomes (unconjugated li- concentrations were 0.3 and 1.0 AU/ml, which is comparable 
posomes and irrelevant RIV1000 immunoliposomes) are not to the situation in patients. If necessary, it will be in principle 
toxic for the cells under these conditions, due to inactivation possible to boost the level of circulating AT antibodies by 
by the co-incubated AT antibodies. Apparently, DT is cyto- (re)vaccination of the patients with diphtheria toxoid prior 
toxic only when incorporated in tumor-specific mmunolipo- to therapy with DT immunoliposomes. 
somes. This suggests that cell binding of DT immunolipo- In conclusion, tumor-specific DT immunoliposomes can 
somes is required for the induction of antitumor activity, provide protection against he non-specific action of DT and 
The crucial importance of cell binding for achieving antitumor display efficient antitumor activity even in the presence of AT 
activity is underlined by our observations that DT-liposomes antibodies. We expect that the proposed DT immunolipo- 
are not active when they lack a specific antibody and that the some-based approach for the delivery of DT will not result 
antitumor activity of specific immunoliposomes increases with in considerable toxicity for the patient: any DT molecules 
increasing Fab'  density on their surface (Fig. 5). In view of released prematurely from the immunoliposomes before tu- 
the requirement of cell binding for achieving cytotoxicity, no mor cell binding will be inactivated by circulating antibodies 
bystander effect of this treatment is to be expected. Therefore, as most patients will be vaccinated against DT. Depending on 
multiple injection schemes are required to reach cells which the liposomes, site of administration, and tumor type, a large 
will not be in contact with the immunoliposomes after the first fraction of immunoliposomes can be bound to tumor cells. 
injection. Such repeated osage regimens will not be effective Unbound immunoliposomes are mainly cleared by cells of 
in the case of free DT due to its immunogenicity, the mononuclear phagocyte system (MPS). In view of poten- 
The mechanism behind the antitumor activity of tumor-spe- tial toxic effects, MPS uptake can be considered as advanta- 
cific DT immunoliposomes displayed in the presence of AT geous, as the immunoliposomes will end up in the lysosomal 
antibodies i  not clear yet. We have reported earlier that cell- compartment of these cells and most toxins are degraded by 
bound OV-TL3 immunoliposomes are hardly endocytosed by lysosomal enzymes [32]. 
ovarian cancer cells [12]. The observation that the presence of This completely new concept might yield an effective and in 
AT antibodies during the 72 h culture period results in a principle low toxicity weapon to fight various forms of cancer 
reduced antitumor effect of cell-bound DT immunoliposomes that are accessible to immunoliposomes. Our future studies 
(Fig. 4) would suggest hat release of DT from cell-bound will particularly focus on the application of this concept for 
immunoliposomes rather than cellular internalization of the the treatment of peritoneal metastases of ovarian carcinoma 
immunoliposomes is involved. In this respect, our approach as efficient arget cell binding in vivo was observed in tumor 
differs from that of Huang and co-workers [7,8]. They encap- bearing mice upon i.p. administration of immunoliposomes 
sulated fragment A of DT (DTA) in pH-sensitive immunoli- [13]. 
posomes. These immunoliposomes are supposed to deliver 
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